Please use this identifier to cite or link to this item:
Title: Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics
Authors: Si, Zhangyong
Hou, Zheng
Vikhe, Yogesh Shankar
Thappeta, Kishore Reddy Venkata
Marimuthu, Kalisvar
De, Partha Pratim
Ng, Oon Tek
Li, Peng
Zhu, Yabin
Pethe, Kevin
Chan-Park, Mary B.
Keywords: Engineering::Chemical engineering::Polymers and polymer manufacture
Issue Date: 2021
Source: Si, Z., Hou, Z., Vikhe, Y. S., Thappeta, K. R. V., Marimuthu, K., De, P. P., Ng, O. T., Li, P., Zhu, Y., Pethe, K. & Chan-Park, M. B. (2021). Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics. ACS Applied Materials & Interfaces, 13(2), 3237-3245.
Project: MOE2013-T3-1-002
H17/01/a0/ 0M9
Journal: ACS Applied Materials & Interfaces 
Abstract: Cationic polymers are promising antibacterial agents since they have a low propensity for bacteria to evolve resistance, but they usually have low biocompatibility due to their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polymer, 2,6-Diamino Chitosan (2,6-DAC). 2,6-DAC shows excellent broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 8-32 µg/mL against clinically relevant and multi-drug resistant (MDR) bacteria including Listeria monocytogenes, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Further, 2,6-DAC shows an excellent synergistic effect with various clinically relevant antibiotics proved by decreasing the MICs of the antibiotics against MDR A. baumannii and MRSA to <1 µg/mL. In vivo biocompatibility of 2,6-DAC is proved by a dosage of 100 mg/kg compound via the oral administration and 25 mg/kg compound via intraperitoneal injection to mice; 2,6-DAC does not cause any weight loss and any significant change in liver and kidney biomarkers nor the important blood electrolytes. The combinations of 2,6-DAC together with novobiocin and rifampicin show >2.4 log10 reduction of A. baumannii in murine intraperitoneal and lung infection models. The novel chitosan derivative, 2,6-DAC, can be utilized as biocompatible broad-spectrum cationic antimicrobial agent alone or in synergistic combination with various antibiotics.
ISSN: 1944-8244
DOI: 10.1021/acsami.0c20881
Rights: This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Applied Materials & Interfaces, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles
SBS Journal Articles
SCBE Journal Articles

Files in This Item:
File Description SizeFormat 
Manuscript.pdfMain934.12 kBAdobe PDFView/Open
Supporting information.pdfSI2.61 MBAdobe PDFView/Open

Citations 20

Updated on Dec 22, 2021

Citations 20

Updated on Dec 21, 2021

Page view(s)

Updated on Jun 25, 2022


Updated on Jun 25, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.